Enabling the next era of informed cancer care.
Our portfolio of oncology tests empowers insight-driven care at key decision moments.
20+
years of experience
1.5 million
patients benefited
90
countries served
Powering actionable insights, at any stage of care.
No matter where your patient is with their cancer, the Precision Oncology testing portfolio empowers you with personalized insights at key decision moments.
See the portfolio in action for:
Hereditary Test
Screening/Surveillance
Cologuard® Test
Oncoguard® Liver Test
Cancerguard™ multi-cancer early detection (MCED) Test - Innovation in development - Learn more
Molecular Residual Disease
Oncodetect™ Test -
Innovation in development - Learn more
MRD Recurrence Monitoring
Oncodetect Test -
Innovation in development - Learn more
Therapy Selection
OncoExTra™ Test
Oncoliquid™ Test - Innovation in development
Riskguard Hereditary Cancer Test
The OncoComplete™ Portfolio: Our comprehensive cancer testing portfolio responds to your patient’s needs before diagnosis, through treatment selection, and in the event of relapse or recurrence.
Learn about the Exact Sciences mission to reduce cancer deaths by 50% in the next 25 years—and the action plan that will help make it happen.
Discover how the different tests in the Precision Oncology testing portfolio help provide valuable insights at key moments in a patient’s cancer journey.
The Precision Oncology Promise
Enabling you to make treatment decisions as individual as each patient.
- Apply advanced genomic science to reveal the unique biology of a patient’s condition
- Streamline testing across cancer types and treatment stages
- Help find the most appropriate therapeutic choice for optimal care management
- Intelligent tests for smart answers from risk assessment to therapy selection
- Connecting programs and products on the same IT and digital infrastructure for an enhanced experience
- A one-stop shop testing hub allows for efficient shifting between patient needs
- Experience innovation through collaborations with elite institutions, creating more industry-shifting opportunities
- Participate in data collaboration to elevate evidence-based decisions
- Shift from fee-for-service to episode-of-care
How are we helping to support you?
By delivering on the high-quality testing and answers you need in a streamlined and personalized way.
The Cologuard test has been reviewed and approved by the FDA as an In Vitro Diagnostic (IVD). All other on- market tests listed were developed, and the performance characteristics validated by an Exact Sciences clinical laboratory following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. These tests have not been cleared or approved by the US Food and Drug Administration. For more information on each test, see ExactSciences.com.
We believe that taking a holistic view of a patient’s present and future testing needs across the care continuum can create meaningful change in progress against cancer.
Let’s change lives, together.